title: The prognostic relevance of flt3 and npm1 mutations on older patients treated intensively or non-intensively: a study of 1312 patients in the UK NCRI AML16 trial.
abstract: Although the prognostic impact of mutations of FLT3 and NPM1 have been extensively studied in younger patients with acute myeloid leukaemia, less is known in older patients whether treated intensively or non-intensively, or in the context of existing prognostic scores. In 1312 patients 16 and 21%, respectively had an FLT3 and NPM1 mutation. An FLT3 mutation did not affect remission rate in intensively or non-intensively treated patients but was associated with an inferior survival. All patients with an NPM1c mutation had a significantly higher remission rate irrespective of treatment approach but survival was not improved, overall, or in any genotype except as in younger patients, in the FLT3 WT NPM1c mutant subgroup. When incorporated into an established multi-parameter prognostic risk score, the molecular information provided additional prognostic definition in 11% of patients.
authors.affiliation: 1] Department of Haematology, School of Medicine, Cardiff University, Cardiff, UK [2] Cardiff Experimental Cancer Medicine Centre, Cardiff, UK.
authors.forename: M
authors.initials: M
authors.lastname: Lazenby
authors.affiliation: Department of Haematology, School of Medicine, Cardiff University, Cardiff, UK.
authors.forename: A F
authors.initials: AF
authors.lastname: Gilkes
authors.affiliation: Department of Haematology, School of Medicine, Cardiff University, Cardiff, UK.
authors.forename: C
authors.initials: C
authors.lastname: Marrin
authors.affiliation: Department of Haematology, School of Medicine, Cardiff University, Cardiff, UK.
authors.forename: A
authors.initials: A
authors.lastname: Evans
authors.affiliation: Department of Haematology, School of Medicine, Cardiff University, Cardiff, UK.
authors.forename: R K
authors.initials: RK
authors.lastname: Hills
authors.affiliation: 1] Department of Haematology, School of Medicine, Cardiff University, Cardiff, UK [2] Cardiff Experimental Cancer Medicine Centre, Cardiff, UK.
authors.forename: A K
authors.initials: AK
authors.lastname: Burnett
mesh_terms: D000368:Aged; D005260:Female; D005838:Genotype; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy* / Q000235:genetics*; D008297:Male; D008875:Middle Aged; D009154:Mutation; D009687:Nuclear Proteins / Q000235:genetics*; D000090243:Nucleophosmin; D011379:Prognosis; D012008:Recurrence; D012074:Remission Induction; D012306:Risk; D016896:Treatment Outcome; D006113:United Kingdom; D051941:fms-Like Tyrosine Kinase 3 / Q000235:genetics*
chemical_list: C000716967:NPM1 protein, human; D009687:Nuclear Proteins; D000090243:Nucleophosmin; C497970:FLT3 protein, human; D051941:fms-Like Tyrosine Kinase 3